I agree, killing off the mono trial once the pivot

I agree, killing off the mono trial once the pivotal is approved, you are looking at saving cutting 70% of burn rate. Also, if management agrees to reduce salary until BLA, they could reduce burn to maybe 1M per month. They have 100M shares available for deals, when they get rid of the note holder that frees up 50M shares. Also, I wouldn‘t be opposed to them raising more to get rid of note holder, then that frees up those 50M, so they would be gaining shares or at least a wash, but getting them out of the way.